NASDAQ:KTTA Pasithea Therapeutics 3/24/2025 Earnings Report $0.79 -0.04 (-5.21%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.02 (+2.29%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Pasithea Therapeutics EPS ResultsActual EPS-$2.41Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APasithea Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APasithea Therapeutics Announcement DetailsQuarterDate3/24/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsPasithea Therapeutics' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Pasithea Therapeutics Earnings HeadlinesPasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory DiseasesJune 12 at 7:49 PM | nasdaq.comPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardJune 11 at 7:02 AM | globenewswire.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.June 13, 2025 | Crypto 101 Media (Ad)Pasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025June 5, 2025 | nasdaq.comPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025June 2, 2025 | globenewswire.comPasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory DiseasesMay 21, 2025 | nasdaq.comSee More Pasithea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email. Email Address About Pasithea TherapeuticsPasithea Therapeutics (NASDAQ:KTTA), a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.View Pasithea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Wells Fargo & Company (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
